TY - JOUR
T1 - Evaluation of two treatment strategies for the prevention of preterm birth in women identified as at risk by ultrasound (PESAPRO Trial)
T2 - Study protocol for a randomized controlled trial
AU - Cabrera-García, Lourdes
AU - Cruz-Melguizo, Sara
AU - Ruiz-Antorán, Belén
AU - Torres, Ferrán
AU - Velasco, Ana
AU - Martínez-Payo, Cristina
AU - Avendaño-Solá, Cristina
AU - Melguizo, Sara Cruz
AU - Cordero, Estefanía
AU - Burgos, Begoña Adiego
AU - Guisasola, Javier Martínez
AU - Cortés, Luis Martínez
AU - González, Celso García
AU - Segura, Gonzalo Quesada
AU - Abarca, Leopoldo
AU - Savirón, Ricardo
AU - Carbajo, Esther Pérez
AU - Rodríguez León, José Alberto
AU - Bartha, José Luis
AU - Teulón, María
AU - Nogales, Rosa
AU - Rodríguez, null
AU - Alonso, Gregoria
AU - Colomo, Cristina Álvarez
AU - Anaya Baz, Mángeles
AU - Davó, Daniel Abehsera
AU - Cancelo, Maria Jesús
AU - De Teran, Elisa Maria Díaz
AU - Mateu Pruñunosa, Joan Carles
AU - Gálvez, Gloria
AU - Torre, Antoniodela
AU - Marqueta Sánchez, José Manuel
AU - Bermejo, Rosa
AU - Artola, Arantza Lekuona
AU - Rodríguez, Eduardo Cabrillo
AU - deDios, Emilia
PY - 2015/9/25
Y1 - 2015/9/25
N2 - Background: Premature birth is considered one of the main problems in modern Obstetrics. It causes more than 50 % of neonatal mortality; it is responsible for a large proportion of infant morbidity and incurs very high economic costs. Cervical length, which can be accurately measured by ultrasound, has an inverse relationship with the risk of preterm birth. As a result, having an effective intervention for asymptomatic patients with short cervix could reduce the prematurity. Although recently published data demonstrates the effectiveness of vaginal progesterone and cervical pessary, these treatments have never been compared to one another. Methods/Design: The PESAPRO study is a noncommercial, multicenter, open-label, randomized clinical trial (RCT) in pregnant women with a short cervix as identified by transvaginal ultrasonography at 19 to 22 weeks of gestation. Patients are randomized (1:1) to either daily vaginal progesterone or cervical pessary until the 37th week of gestation or delivery; whichever comes first. During the trial, women visit every 4 weeks for routine questions and tests. The primary outcome is the proportion of spontaneous preterm deliveries before 34 weeks of gestation. A sample size of 254 pregnant women will be included at 29 participating hospitals in order to demonstrate noninferiority of placing a pessary versus vaginal progesterone. The first patient was randomized in August 2012, and recruitment of study subjects will continue until the end of December 2015. Discussion: This trial assesses the comparative efficacy and safety between two accepted treatments, cervical pessary versus vaginal progesterone, and it will provide evidence in order to establish clinical recommendations. Trial registration: EU Clinical Trials Register EudraCT2012-000241-13 (Date of registration: 16 January 2012); ClinicalTrials.gov Identifier NCT01643980(Date of registration: 12 June 2012).
AB - Background: Premature birth is considered one of the main problems in modern Obstetrics. It causes more than 50 % of neonatal mortality; it is responsible for a large proportion of infant morbidity and incurs very high economic costs. Cervical length, which can be accurately measured by ultrasound, has an inverse relationship with the risk of preterm birth. As a result, having an effective intervention for asymptomatic patients with short cervix could reduce the prematurity. Although recently published data demonstrates the effectiveness of vaginal progesterone and cervical pessary, these treatments have never been compared to one another. Methods/Design: The PESAPRO study is a noncommercial, multicenter, open-label, randomized clinical trial (RCT) in pregnant women with a short cervix as identified by transvaginal ultrasonography at 19 to 22 weeks of gestation. Patients are randomized (1:1) to either daily vaginal progesterone or cervical pessary until the 37th week of gestation or delivery; whichever comes first. During the trial, women visit every 4 weeks for routine questions and tests. The primary outcome is the proportion of spontaneous preterm deliveries before 34 weeks of gestation. A sample size of 254 pregnant women will be included at 29 participating hospitals in order to demonstrate noninferiority of placing a pessary versus vaginal progesterone. The first patient was randomized in August 2012, and recruitment of study subjects will continue until the end of December 2015. Discussion: This trial assesses the comparative efficacy and safety between two accepted treatments, cervical pessary versus vaginal progesterone, and it will provide evidence in order to establish clinical recommendations. Trial registration: EU Clinical Trials Register EudraCT2012-000241-13 (Date of registration: 16 January 2012); ClinicalTrials.gov Identifier NCT01643980(Date of registration: 12 June 2012).
KW - cervical pessary
KW - premature birth
KW - prevention
KW - short cervix
KW - vaginal progesterone
UR - http://www.scopus.com/inward/record.url?scp=84942083053&partnerID=8YFLogxK
U2 - 10.1186/s13063-015-0964-y
DO - 10.1186/s13063-015-0964-y
M3 - Artículo
C2 - 26407852
AN - SCOPUS:84942083053
SN - 1745-6215
VL - 16
JO - Trials
JF - Trials
IS - 1
M1 - 427
ER -